Transatlantique Private Wealth LLC Genmab A/S Transaction History

Transatlantique Private Wealth LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jun 25, 2024	BUY	$35.27 - $42.24 $221,178 - $264,887	6,271 New	6,271 $221,000
Q2 2023 Jun 25, 2024	SELL	$37.4 - $42.94 $54,865 - $62,992	-1,467 Reduced 18.96%	6,271 $238,000
Q2 2023 Aug 10, 2023	SELL	$37.4 - $42.94 $54,865 - $62,992	-1,467 Reduced 18.96%	6,271 $238,000
Q1 2023 Jun 25, 2024	BUY	$34.88 - $43.22 $269,901 - $334,436	7,738 New	7,738 $292,000
Q1 2023 May 05, 2023	SELL	$34.88 - $43.22 $30,171 - $37,385	-865 Reduced 10.05%	7,738 $292,000
Q4 2022 Jun 25, 2024	BUY	$33.8 - $47.06 $290,781 - $404,857	8,603 New	8,603 $364,000
Q3 2022 Nov 04, 2022	BUY	$31.52 - $373.61 $271,166 - $3.21 Million	8,603 New	8,603 $276,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Transatlantique Private Wealth LLC, based on Form 13F filings with the SEC.

Stay updated on Transatlantique Private Wealth LLC with notifications on news.